|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 10/05/16 Angiodynamics Inc 10-Q 8/31/16 70:4.8M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 383K
2: EX-10.1 Material Contract HTML 59K
3: EX-10.2 Material Contract HTML 57K
4: EX-10.3 Material Contract HTML 115K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
15: R1 Document and Entity Information HTML 41K
16: R2 Consolidated Condensed Statements of Income (Loss) HTML 83K
(Unaudited)
17: R3 Consolidated Condensed Statements of Comprehensive HTML 48K
Income (Loss) (Unaudited)
18: R4 Consolidated Condensed Balance Sheets (Unaudited) HTML 110K
19: R5 Consolidated Condensed Balance Sheets (Unaudited) HTML 44K
(Parenthetical)
20: R6 Consolidated Condensed Statements of Cash Flows HTML 94K
(Unaudited)
21: R7 Consolidated Condensed Statement of Stockholders' HTML 72K
Equity (Unaudited)
22: R8 Consolidated Condensed Financial Statements HTML 29K
23: R9 Inventories HTML 31K
24: R10 Other Assets HTML 25K
25: R11 Goodwill and Intangible Assets HTML 77K
26: R12 Accrued Liabilities HTML 35K
27: R13 Long Term Debt HTML 30K
28: R14 Income Taxes HTML 43K
29: R15 Share-Based Compensation HTML 30K
30: R16 Earnings Per Share HTML 33K
31: R17 Segment and Geographic Information HTML 47K
32: R18 Fair Value HTML 124K
33: R19 Marketable Securities HTML 53K
34: R20 Commitments and Contingencies HTML 43K
35: R21 Recently Issued Accounting Pronouncements HTML 37K
36: R22 Restructuring HTML 24K
37: R23 Recently Issued Accounting Pronouncements HTML 33K
(Policies)
38: R24 Inventories (Tables) HTML 32K
39: R25 Goodwill and Intangible Assets (Tables) HTML 67K
40: R26 Accrued Liabilities (Tables) HTML 35K
41: R27 Income Taxes (Tables) HTML 39K
42: R28 Earnings Per Share (Tables) HTML 31K
43: R29 Segment and Geographic Information (Tables) HTML 44K
44: R30 Fair Value (Tables) HTML 117K
45: R31 Marketable Securities (Tables) HTML 47K
46: R32 Inventories - Schedule of Inventories (Detail) HTML 29K
47: R33 Other Assets (Details) HTML 26K
48: R34 Goodwill and Intangible Assets - Additional HTML 25K
Information (Detail)
49: R35 Goodwill and Intangible Assets - Intangible Assets HTML 57K
(Detail)
50: R36 Accrued Liabilities - Summary of Accrued HTML 41K
Liabilities (Detail)
51: R37 Long Term Debt - Additional Information (Detail) HTML 74K
52: R38 Income Taxes - Components of Income Tax HTML 40K
Expense/(Benefit) (Detail)
53: R39 Income Taxes - Additional Information (Detail) HTML 22K
54: R40 Share-Based Compensation (Details) HTML 36K
55: R41 Earnings Per Share - Reconciliation of Basic to HTML 32K
Diluted Weighted-Average Shares Outstanding
(Detail)
56: R42 Segment and Geographic Information - Additional HTML 22K
Information (Detail)
57: R43 Segment and Geographic Information - Summary of HTML 31K
Net Sales by Product Category (Detail)
58: R44 Segment and Geographic Information - Summary of HTML 31K
Net Sales by Geographic Area (Detail)
59: R45 Fair Value - Additional Information (Detail) HTML 21K
60: R46 Fair Value - Fair Value of Assets and Liabilities HTML 52K
Measured on a Recurring Basis (Detail)
61: R47 Fair Value - Fair Value Measurements Using HTML 41K
Significant Unobservable Inputs (Detail)
62: R48 Fair Value - Summary Showing the Recurring Fair HTML 50K
Value Measurements of the Contingent Consideration
Liability (Detail)
63: R49 Marketable Securities - Additional Information HTML 24K
(Detail)
64: R50 Marketable Securities - Marketable Securities HTML 34K
(Detail)
65: R51 Commitments and Continfencies - Additional HTML 58K
Information (Detail)
66: R52 Recently Issued Accounting Pronouncements HTML 28K
(Details)
67: R53 Restructuring - Additional Information (Detail) HTML 26K
69: XML IDEA XML File -- Filing Summary XML 117K
68: EXCEL IDEA Workbook of Financial Reports XLSX 63K
9: EX-101.INS XBRL Instance -- ango-20160831 XML 1.19M
11: EX-101.CAL XBRL Calculations -- ango-20160831_cal XML 183K
12: EX-101.DEF XBRL Definitions -- ango-20160831_def XML 358K
13: EX-101.LAB XBRL Labels -- ango-20160831_lab XML 1.13M
14: EX-101.PRE XBRL Presentations -- ango-20160831_pre XML 625K
10: EX-101.SCH XBRL Schema -- ango-20160831 XSD 130K
70: ZIP XBRL Zipped Folder -- 0001275187-16-000037-xbrl Zip 143K
| Exhibit |
1. | I have reviewed this quarterly report on Form 10-Q of AngioDynamics, Inc.; | |
2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
4. | The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
(b) | Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
(c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
(d) | Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and | |
5. | The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): | |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and
report financial information; and | |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/5/16 | 8-K | ||
| For Period end: | 8/31/16 | 10-Q/A, 4 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/03/23 Angiodynamics Inc. 10-K 5/31/23 112:11M Workiva Inc Wde… FA01/FA 7/22/22 Angiodynamics Inc. 10-K 5/31/22 106:11M 7/27/21 Angiodynamics Inc. 10-K 5/31/21 110:11M 8/10/20 Angiodynamics Inc. 10-K 5/31/20 118:15M |